SC0245
Small Cell Lung Cancer (SCLC)
Phase 1IND approved (2020)
Key Facts
Indication
Small Cell Lung Cancer (SCLC)
Phase
Phase 1
Status
IND approved (2020)
Company
About BioCity Biopharma
A clinical-stage biopharma developing novel BIC/FIC therapeutics for oncology and nephrology, with a multi-modality pipeline and global clinical operations.
View full company profileTherapeutic Areas
Other Small Cell Lung Cancer (SCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tarlatamab (AMG 757) | Amgen | Phase 3 |
| Iadademstat (ORY-1001) | Oryzon Genomics | Phase II |